DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Basimglurant
Basimglurant
Abstract Book – Oral Sessions
Brain Metabolic Profile After Intranasal Vs. Intraperitoneal Clomipramine
AHRQ Healthcare Horizon Scanning System – Status Update
Understanding Exposure-Receptor Occupancy Relationships For
LJMU Research Online
Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Mglu5 Negative Allosteric Modulator in Clinical Development for Depression
'Party Drug' Turned Antidepressant Approaches Approval
Fragile X Targeted Pharmacotherapy: Lessons Learned and Future Directions Craig A
Depression and Schizophrenia Viewed from the Perspective of Amino Acidergic Neurotransmission: Antipodes of Psychiatric Disorders
Stembook 2018.Pdf
Tuesday, June 23, 2015
Towards Mechanism- Based Treatments for Fragile X Syndrome
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Orphan Drug Designation List
Poster Session Iituesday, December 09, 2014
International Nonproprietary Names for Pharmaceutical Substances (INN)
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Profiling the Structural Determinants of Aryl Benzamide Derivatives As
Top View
Fragile X Syndrome: a Review of Clinical Management
Program Book
Effect of the Mglur5-NAM Basimglurant on Behavior In
[18F]FPEB Binding to Metabotropic Glutamate Receptor Subtype
MPEP, a Metabotropic Glutamate Receptor 5 (Mglur5) Negative Allosteric Modulator, Protects from Hepatic Ischemic Injury Both in Vitro and Ex Vivo
A Combination of Ascorbic Acid and Α-Tocopherol to Test The
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Treatment of the Psychiatric Problems Associated with Fragile X Syndrome
Pubmed Search Strategy ("Autistic Disorder"[MH] OR "Autism
A New Generation of Antidepressants: an Update on the Pharmaceutical
Yo U Are P Ro H Ib Ited from M Aking Th Is PDF Pub
Reduced Mglur5 Activity Modulates Mitochondrial Function
Efficacy and Safety of Basimglurant As Adjunctive
Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized S
A Combination of Ascorbic Acid and A
Controlled Trial of Ganaxolone in Children and Adolescents with Fragile X Syndrome Andrew Ligsay1,2†, Anke Van Dijck3,4†, Danh V
Drug-Responsive Autism Phenotypes in the 16P11.2 Deletion Mouse Model
312613629-Oa
Treatment-Resistant Depression (TRD) Maurizio Fava, MD
Experimental Medication Treatment Approaches for Depression
Chapter 4 Draft
Book of Abstracts 2016
Genetic Basis of Intellectual Disability and Schizophrenia in Selected Omani and UK Families
Label Noise in Subtype Discrimination of Class CG Protein-Coupled Receptors
Ac79a99defd346f1533f06cf84e4
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016